Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi)

This study is currently recruiting participants.

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, we'll continue the study, but only accrue patients with peripheral T-Cell lymphoma (PTCL).

Study Type:  Interventional

Study Design:  

Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma

Conditions:  

Lymphoid Malignancies
Multiple Myeloma
Lymphoma
Hodgkin Lymphoma
Non-hodgkin Lymphoma

Interventions:  

Drug: Pralatrexate
Drug: Romidepsin

Phase:  Phase 1, Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT01947140